Alterationsinarterial pressureinpatients with Type1diabetes are associated with long-term poor metabolic control andamore atherogenic lipid profile

2010 ◽  
Vol 34 (2) ◽  
pp. e24-e29 ◽  
Author(s):  
F. J. Vílchez-López ◽  
F. Carral-Sanlaureano ◽  
C. Coserria-Sánchez ◽  
A. Nieto ◽  
S. Jiménez ◽  
...  
Keyword(s):  
Lipid Profile ◽  
Metabolic Control ◽  
Poor Metabolic Control ◽  
Atherogenic Lipid Profile ◽  
Atherogenic Lipid

Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long‐term infliximab therapy

2006 ◽  
Vol 35 (2) ◽  
pp. 107-111 ◽  
Author(s):  
S. Rantapää Dahlqvist ◽  
S. Engstrand ◽  
E. Berglin ◽  
O Johnson
Keyword(s):  
Rheumatoid Arthritis ◽  
Lipid Profile ◽  
Infliximab Therapy ◽  
Atherogenic Lipid Profile ◽  
Atherogenic Lipid

scholarly journals Insulin-Mediated Glucose Metabolism: An Atherogenic Lipid Profile of Fructose Consumption

2018 ◽  
Vol 2 (2) ◽  
pp. 01-02
Author(s):  
Elizabeth Kagotho
Keyword(s):  
Lipid Profile ◽  
Positive Energy ◽  
Sweetened Beverages ◽  
Atherogenic Lipid Profile ◽  
High Fructose ◽  
Short And Long Term ◽  
Postprandial Triacylglycerol ◽  
Atherogenic Lipid ◽  
Long Term Studies

Our laboratory has investigated two hypotheses regarding the effects of fructose consumption: 1) The endocrine effects of fructose consumption favor a positive energy balance, and 2) Fructose consumption promotes the development of an atherogenic lipid profile. In previous short- and long-term studies, we demonstrated that consumption of fructose-sweetened beverages with 3 meals results in lower 24-hour plasma concentrations of glucose, insulin, and leptin in humans compared with consumption of glucose-sweetened beverages. We have also tested whether prolonged consumption of high-fructose diets could lead to increased caloric intake or decreased energy expenditure, thereby contributing to weight gain and obesity. Results from a study conducted in rhesus monkeys produced equivocal results. Carefully controlled and adequately powered long-term studies are needed to address these hypotheses. In both short- and long-term studies we demonstrated that consumption of fructose-sweetened beverages substantially increases postprandial triacylglycerol concentrations compared with glucose-sweetened beverages. In the long-term studies, apolipoproteinB concentrations were also increased in subjects consuming fructose, but not those consuming glucose. Data from a short-term study comparing consumption of beverages sweetened with fructose, glucose, high fructose corn syrup (HFCS) and sucrose, suggest that HFCS and sucrose increase postprandial triacylglycerol to an extent comparable to that induced by 100% fructose alone. Increased consumption of fructose-sweetened beverages along with increased prevalence of obesity, metabolic syndrome, and type 2 diabetes underscore the importance of investigating the metabolic consequences fructose consumption in carefully controlled experiments.

scholarly journals Insulin-Mediated Glucose Metabolism: An Atherogenic Lipid Profile of Fructose Consumption

2018 ◽  
Vol 2 (2) ◽  
pp. 01-02
Author(s):  
Elizabeth Kagotho
Keyword(s):  
Lipid Profile ◽  
Positive Energy ◽  
Sweetened Beverages ◽  
Atherogenic Lipid Profile ◽  
High Fructose ◽  
Short And Long Term ◽  
Postprandial Triacylglycerol ◽  
Atherogenic Lipid ◽  
Long Term Studies

Our laboratory has investigated two hypotheses regarding the effects of fructose consumption: 1) The endocrine effects of fructose consumption favor a positive energy balance, and 2) Fructose consumption promotes the development of an atherogenic lipid profile. In previous short- and long-term studies, we demonstrated that consumption of fructose-sweetened beverages with 3 meals results in lower 24-hour plasma concentrations of glucose, insulin, and leptin in humans compared with consumption of glucose-sweetened beverages. We have also tested whether prolonged consumption of high-fructose diets could lead to increased caloric intake or decreased energy expenditure, thereby contributing to weight gain and obesity. Results from a study conducted in rhesus monkeys produced equivocal results. Carefully controlled and adequately powered long-term studies are needed to address these hypotheses. In both short- and long-term studies we demonstrated that consumption of fructose-sweetened beverages substantially increases postprandial triacylglycerol concentrations compared with glucose-sweetened beverages. In the long-term studies, apolipoproteinB concentrations were also increased in subjects consuming fructose, but not those consuming glucose. Data from a short-term study comparing consumption of beverages sweetened with fructose, glucose, high fructose corn syrup (HFCS) and sucrose, suggest that HFCS and sucrose increase postprandial triacylglycerol to an extent comparable to that induced by 100% fructose alone. Increased consumption of fructose-sweetened beverages along with increased prevalence of obesity, metabolic syndrome, and type 2 diabetes underscore the importance of investigating the metabolic consequences fructose consumption in carefully controlled experiments.

scholarly journals Advanced Lipoprotein Analysis Shows Atherogenic Lipid Profile That Improves After Metreleptin in Patients with Lipodystrophy

2019 ◽  
Vol 3 (8) ◽  
pp. 1503-1517 ◽  
Author(s):  
Alexandra B Kinzer ◽  
Robert D Shamburek ◽  
Marissa Lightbourne ◽  
Ranganath Muniyappa ◽  
Rebecca J Brown
Keyword(s):  
Insulin Resistance ◽  
High Density Lipoprotein ◽  
Lipid Profile ◽  
Density Lipoprotein ◽  
High Density ◽  
Lipoprotein Profile ◽  
Cvd Risk ◽  
Lipoprotein Particles ◽  
Atherogenic Lipid Profile ◽  
Atherogenic Lipid

Abstract Context Patients with lipodystrophy have dyslipidemia and insulin resistance. Leptin treatment with metreleptin in lipodystrophy decreases insulin resistance and lowers triglycerides without changing high-density lipoprotein. Detailed measurement of lipoprotein particles with nuclear magnetic resonance (NMR) spectroscopy can offer insights into cardiovascular disease (CVD) risk and lipid metabolism beyond a standard lipid panel. We hypothesized that patients with lipodystrophy would have a more atherogenic lipid profile than controls at baseline, which would be ameliorated with metreleptin treatment. Objective To characterize the lipoprotein profile in patients with lipodystrophy compared with controls and to evaluate effects of metreleptin treatment. Design, Setting, Patients, and Intervention Patients with lipodystrophy (N = 17) were studied before and after metreleptin for 2 weeks and 6 months and compared with 51 insulin-sensitive sex-matched controls. Main Outcome Measures Lipoprotein profiles were measured by NMR with the LP4 deconvolution algorithm, which reports triglyceride-rich lipoprotein particles (TRLPs), high-density lipoprotein particles (HDLPs), and low-density lipoprotein particles (LDLPs). Results Patients with lipodystrophy had elevated large TRLPs and smaller HDLPs and LDLPs compared with controls. Five patients with lipodystrophy had chylomicrons, compared with zero controls. Metreleptin decreased the size and concentration of TRLPs, eliminated chylomicrons in all but one patient, decreased LDLPs, and increased LDLP size. Metreleptin treatment did not have major effects on HDLPs. Conclusions Patients with lipodystrophy had an atherogenic lipoprotein profile at baseline consistent with elevated CVD risk, which improved after metreleptin treatment. The presence of fasting chylomicrons in a subset of patients with lipodystrophy suggests saturation of chylomicron clearance by lipoprotein lipase.

W02-O-002 The APOB-516C/T polymorphism isassociated with a more atherogenic lipid profile in males independently of the consumption of dietary fat

2005 ◽  
Vol 6 (1) ◽  
pp. 7
Author(s):  
P. Perez-Martinez ◽  
J. Lopez-Miranda ◽  
A. Lozano ◽  
J.A. Moreno ◽  
C. Bellido ◽  
...  
Keyword(s):  
Lipid Profile ◽  
Dietary Fat ◽  
Atherogenic Lipid Profile ◽  
Atherogenic Lipid

scholarly journals Decreased adiponectin levels in familial combined hyperlipidemia patients contribute to the atherogenic lipid profile

2005 ◽  
Vol 46 (11) ◽  
pp. 2398-2404 ◽  
Author(s):  
Gerly M. van der Vleuten ◽  
Lambertus J. H. van Tits ◽  
Martin den Heijer ◽  
Heidi Lemmers ◽  
Anton F. H. Stalenhoef ◽  
...  
Keyword(s):  
Lipid Profile ◽  
Familial Combined Hyperlipidemia ◽  
Atherogenic Lipid Profile ◽  
Atherogenic Lipid

PM367 Stable Angina Pectoris And Diabetes Mellitus Of Type 2: The Role Of The Atherogenic Lipid Profile And Inflammatory Markers

Global Heart ◽  
2014 ◽  
Vol 9 (1) ◽  
pp. e136
Author(s):  
Ludmila Gapon ◽  
Tatiana Petelina ◽  
Natalia Musikhina ◽  
Natalia Dementjeva ◽  
Vadim Kuznetsov
Keyword(s):  
Diabetes Mellitus ◽  
Angina Pectoris ◽  
Lipid Profile ◽  
Stable Angina ◽  
Inflammatory Markers ◽  
Stable Angina Pectoris ◽  
Atherogenic Lipid Profile ◽  
Atherogenic Lipid

scholarly journals Alterations in Lipids and Adipocyte Hormones in Female-to-Male Transsexuals

2010 ◽  
Vol 2010 ◽  
pp. 1-4 ◽  
Author(s):  
Prakash Chandra ◽  
Sukhdeep S. Basra ◽  
Tai C. Chen ◽  
Vin Tangpricha
Keyword(s):  
Lipid Profile ◽  
Total Cholesterol ◽  
Statistical Significance ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Testosterone Therapy ◽  
Serum Leptin ◽  
Atherogenic Lipid Profile

Testosterone therapy in men and women results in decreased high-density lipoprotein cholesterol (HDL) and increased low-density lipoprotein cholesterol (LDL). We sought to determine whether testosterone therapy has this same effect on lipid parameters and adipocyte hormones in female-to-male (FTM) transsexuals. Twelve FTM transsexuals provided a fasting lipid profile including serum total cholesterol, HDL, LDL, and triglycerides prior to and after 1 year of testosterone therapy (testosterone enanthate or cypionate 50–125 mg IM every two weeks). Subjects experienced a significant decrease in mean serum HDL (52±11to40±7 mg/dL)(P<.001). The mean LDL(P=.316), triglyceride(P=.910), and total cholesterol(P=.769)levels remained unchanged. In a subset of subjects, we measured serum leptin levels which were reduced by 25% but did not reach statistical significance(P=.181)while resistin levels remained unchanged. We conclude that testosterone therapy in FTM transsexuals can promote an increased atherogenic lipid profile by lowering HDL and possibly reduce serum leptin levels. However, long-term studies are needed to determine whether decreases in HDL result in adverse cardiovascular outcomes.

Sign in / Sign up

Export Citation Format

Share Document